文献速递心脑血管急症消化、代谢与肾脏急症

他汀类药物对糖尿病及心血管病风险人群非高密度脂蛋白胆固醇的比较有效性:系统评价与网状Meta分析

Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.
PubMed 文献 · BMJ · 2022-03-24
一句话结论网状Meta分析显示,瑞舒伐他汀中高强度和辛伐他汀、阿托伐他汀高强度降低糖尿病患者非高密度脂蛋白胆固醇最有效,阿托伐他汀中等强度可显著减少非致死性心肌梗死。

该研究为系统评价与网状Meta分析,纳入42项随机对照试验共20193名1型或2型糖尿病成人,其中11698人进入Meta分析,比较不同种类和强度他汀对非高密度脂蛋白胆固醇(non-HDL-C)的影响。结果显示,与安慰剂相比,瑞舒伐他汀高强度(-2.31 mmol/L,95%可信区间-3.39至-1.21)和中等强度(-2.27,-3.00至-1.49)、辛伐他汀高强度(-2.26,-2.99至-1.51)、阿托伐他汀高强度(-2.20,-2.69至-1.70)降低non-HDL-C幅度最大。在心血管事件高风险患者中,阿托伐他汀高强度降低non-HDL-C最多(-1.98,-4.16至0.26),但可信区间跨0。阿托伐他汀中等强度较安慰剂显著减少非致死性心肌梗死(RR=0.57,95%CI 0.43-0.76,n=4项研究)。作者认为,若以降低non-HDL-C为主要目标,该结果可为选择他汀种类和强度提供指导。

要点

  • 与安慰剂相比,瑞舒伐他汀高强度(-2.31 mmol/L,95%可信区间-3.39至-1.21)和中等强度(-2.27,-3.00至-1.49)降低糖尿病患者non-HDL-C幅度最大。
  • 辛伐他汀高强度(-2.26,-2.99至-1.51)和阿托伐他汀高强度(-2.20,-2.69至-1.70)同样显著降低non-HDL-C。
  • 在心血管事件高风险患者(n=4670)中,阿托伐他汀高强度降低non-HDL-C最多(-1.98,-4.16至0.26),但95%可信区间跨0,未达统计学显著。
  • 阿托伐他汀中等强度较安慰剂显著减少非致死性心肌梗死(RR=0.57,95%CI 0.43-0.76,n=4项研究)。
  • 停药、非致死性卒中和心血管死亡在各他汀间无显著差异。

适用人群与场景

  • 成人1型或2型糖尿病患者,来自42项随机对照试验,共20193人,其中11698人进入Meta分析。
  • 亚组分析纳入4670名心血管事件风险较高的患者,与低或中等风险患者比较。

处置流程与药物剂量

  • 与安慰剂相比,瑞舒伐他汀高强度降低non-HDL-C -2.31 mmol/L(95%可信区间-3.39至-1.21),中等强度降低-2.27 mmol/L(-3.00至-1.49)。
  • 与安慰剂相比,辛伐他汀高强度降低non-HDL-C -2.26 mmol/L(95%可信区间-2.99至-1.51),阿托伐他汀高强度降低-2.20 mmol/L(-2.69至-1.70)。
  • 阿托伐他汀和辛伐他汀任意强度及普伐他汀低强度也能有效降低non-HDL-C水平。
  • 在心血管事件高风险患者中,阿托伐他汀高强度降低non-HDL-C -1.98 mmol/L(95%可信区间-4.16至0.26),累积排序曲线下面积64%。

研究设计与关键结果

  • 研究设计为系统评价与网状Meta分析,纳入42项随机对照试验共20193名糖尿病成人,其中11698人进入Meta分析,采用贝叶斯网状Meta分析评估他汀强度(低、中、高)对non-HDL-C的效应,报告均数差和95%可信区间。
  • 与安慰剂相比,瑞舒伐他汀高强度(-2.31 mmol/L,95%可信区间-3.39至-1.21)和中等强度(-2.27,-3.00至-1.49)、辛伐他汀高强度(-2.26,-2.99至-1.51)、阿托伐他汀高强度(-2.20,-2.69至-1.70)降低non-HDL-C幅度最大。
  • 在4670名心血管事件高风险患者中,阿托伐他汀高强度降低non-HDL-C最多(-1.98,-4.16至0.26,累积排序曲线下面积64%)。
  • 辛伐他汀高强度(-1.93,-2.63至-1.21)和瑞舒伐他汀高强度(-1.76,-2.37至-1.15)是降低LDL-C最有效的治疗选择。
  • 阿托伐他汀中等强度较安慰剂显著减少非致死性心肌梗死(RR=0.57,95%CI 0.43-0.76,n=4项研究)。
  • 停药、非致死性卒中和心血管死亡在各他汀间无显著差异。

证据类型、等级与局限

  • 证据类型:系统评价与网状Meta分析,检索Medline、Cochrane对照试验中心注册库和Embase至2021年12月1日,采用CINeMA框架评价证据确定性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,若以降低non-HDL-C为主要目标来预测心血管病,该结果可为选择他汀种类和强度提供指导;瑞舒伐他汀中等和高强度、辛伐他汀和阿托伐他汀高强度在糖尿病患者中降低non-HDL-C最有效。
  • 阿托伐他汀中等强度较安慰剂显著减少非致死性心肌梗死(RR=0.57,95%CI 0.43-0.76,n=4项研究),但停药、非致死性卒中和心血管死亡无显著差异。

指南或共识出处

  • PROSPERO注册号CRD42021258819。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the efficacy of different statin treatments by intensity on levels of non-high density lipoprotein cholesterol (non-HDL-C) for the prevention of cardiovascular disease in people with diabetes.

DESIGN: Systematic review and network meta-analysis.

DATA SOURCES: Medline, Cochrane Central Register of Controlled Trials, and Embase from inception to 1 December 2021.

REVIEW METHODS: Randomised controlled trials comparing different types and intensities of statins, including placebo, in adults with type 1 or type 2 diabetes mellitus were included. The primary outcome was changes in levels of non-HDL-C, calculated from measures of total cholesterol and HDL-C. Secondary outcomes were changes in levels of low density lipoprotein cholesterol (LDL-C) and total cholesterol, three point major cardiovascular events (non-fatal stroke, non-fatal myocardial infarction, and death related to cardiovascular disease), and discontinuations because of adverse events. A bayesian network meta-analysis of statin intensity (low, moderate, or high) with random effects evaluated the treatment effect on non-HDL-C by mean differences and 95% credible intervals. Subgroup analysis of patients at greater risk of major cardiovascular events was compared with patients at low or moderate risk. The confidence in network meta-analysis (CINeMA) framework was applied to determine the certainty of evidence.

RESULTS: In 42 randomised controlled trials involving 20 193 adults, 11 698 were included in the meta-analysis. Compared with placebo, the greatest reductions in levels of non-HDL-C were seen with rosuvastatin at high (-2.31 mmol/L, 95% credible interval -3.39 to -1.21) and moderate (-2.27, -3.00 to -1.49) intensities, and simvastatin (-2.26, -2.99 to -1.51) and atorvastatin (-2.20, -2.69 to -1.70) at high intensity. Atorvastatin and simvastatin at any intensity and pravastatin at low intensity were also effective in reducing levels of non-HDL-C. In 4670 patients at greater risk of a major cardiovascular events, atorvastatin at high intensity showed the largest reduction in levels of non-HDL-C (-1.98, -4.16 to 0.26, surface under the cumulative ranking curve 64%). Simvastatin (-1.93, -2.63 to -1.21) and rosuvastatin (-1.76, -2.37 to -1.15) at high intensity were the most effective treatment options for reducing LDL-C. Significant reductions in non-fatal myocardial infarction were found for atorvastatin at moderate intensity compared with placebo (relative risk=0.57, confidence interval 0.43 to 0.76, n=4 studies). No significant differences were found for discontinuations, non-fatal stroke, and cardiovascular deaths.

CONCLUSIONS: This network meta-analysis indicated that rosuvastatin, at moderate and high intensity doses, and simvastatin and atorvastatin, at high intensity doses, were most effective at moderately reducing levels of non-HDL-C in patients with diabetes. Given the potential improvement in accuracy in predicting cardiovascular disease when reduction in levels of non-HDL-C is used as the primary target, these findings provide guidance on which statin types and intensities are most effective by reducing non-HDL-C in patients with diabetes.

SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42021258819.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Hodkinson A, Tsimpida D, Kontopantelis E, et al. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022. PMID: 35331984. doi:10.1136/bmj-2021-067731

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。